0143-9786 : Enalaprilat 2.5 mg/2ml Intravenous Injection


NDC: 0143-9786
Labeler: West-ward Pharmaceutical Corp
Product Type: Human Prescription Drug
Drug Name: Enalaprilat
Dosage Form: Intravenous Injection
Application #: ANDA078687
Rev. Date: 


NDC Package Codes:

  • 0143-9786-10: 10 VIAL IN 1 CARTON (0143‑9786‑10) > 2 ML IN 1 VIAL (0143‑9786‑01)

Active Ingredients:

  • Enalaprilat

Dosage Strength:

  • 2.5 mg/2mL

Pharmaceutical Classes:

  • Angiotensin Converting Enzyme Inhibitor [EPC]
  • Angiotensin-converting Enzyme Inhibitors [MoA]
  • Decreased Blood Pressure [PE]

Related Products:

Based on records with the same trade name.
  • 0143-9787 Enalaprilat 1.25 mg/ml Intravenous Injection by West-ward Pharmaceutical Corp
  • 0409-2122 Enalaprilat 1.25 mg/ml Intravenous Injection, Solution by Hospira, Inc.
  • 0703-8401 Enalaprilat 1.25 mg/ml Intravenous Injection by Teva Parenteral Medicines, Inc
  • 0703-8411 Enalaprilat 1.25 mg/ml Intravenous Injection by Teva Parenteral Medicines, Inc
  • 43598-078 Enalaprilat 1.25 mg/ml Intravenous Injection by Dr. Reddys Laboratories Inc
  • 43598-169 Enalaprilat 2.5 mg/2ml Intravenous Injection by Dr. Reddys Laboratories Inc
  • 51662-1477 Enalaprilat 1.25 mg/ml Intravenous Injection by Hf Acquisition Co LLC, Dba Healthfirst
  • 55154-0355 Enalaprilat 1.25 mg/ml Intravenous Injection by Cardinal Health
  • 55390-010 Enalaprilat 1.25 mg/ml Intravenous Injection by Bedford Laboratories
  • 55390-011 Enalaprilat 1.25 mg/ml Intravenous Injection by Bedford Laboratories

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0143-9786 QR Code

< Prev: 0143-9785Next: 0143-9787 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.